Drug development deals for Kyowa Hakko/Adimab, Daiichi Sankyo/Amplimmune and Chugai/Debiopharm
Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) and USA-based therapeutic antibody developer Adimab have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against two targets selected by Kyowa Hakko Kirin.
Adimab will receive various upfront fees including research fees and technical milestones. For each target, Kyowa Hakko Kirin will have the sole option to exclusively license antibodies from the collaboration, and if the Japanese firm were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.
Daiichi gets rights to AMP-100
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze